Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Annette Bruls sold 2,644 shares of the company's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares of the company's stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Edwards Lifesciences Trading Up 0.3%
Edwards Lifesciences stock opened at $90.19 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The business's 50-day simple moving average is $89.54 and its 200-day simple moving average is $85.03. The firm has a market capitalization of $51.93 billion, a PE ratio of 51.83, a PEG ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the previous year, the firm earned $0.67 EPS. The firm's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of EW. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences in the 1st quarter valued at $25,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $26,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on EW shares. Mizuho increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Evercore restated an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. BTIG Research upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Finally, UBS Group started coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price target for the company. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.
Get Our Latest Analysis on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
